Memphasys Limited (MEM.AX)
ASX · AUD · Healthcare · Medical Devices
A$0.004 (+0.00%) as of
Key statistics
- Market cap
- 12.38M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0030 – 0.0090
- Beta
- 0.50
- Revenue (TTM)
- 657.97k
- Profit margin
- 0.00%
- Volume
- 111.00k
About Memphasys Limited
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Homebush, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.